Trends in Antiplatelet Therapy Pre and Post Carotid Endarterectomy – A Sticking Point in Current Practice?

Anne Stimpson(Welsh Government), David C. Bosanquet(Cardiff and Vale University Health Board), Rhiannon Harries(Morriston Hospital), Nicola Tanner(Princess of Wales Hospital), Chris Brown(The University of Sydney), Dafydd Loughran(Welsh Government), W. F. Mader(Harbin Institute of Petroleum), Brea Tinsley(Royal Glamorgan Hospital), S. Tate(Royal Glamorgan Hospital), L. Hpkins(Wrexham Maelor Hospital), Scott L. Stevens(University of Tennessee at Knoxville), Kathryn Boyce
International Journal of Surgery
November 1, 2017
10.1016/j.ijsu.2017.08.547
Cited by 0

Related Papers

Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)
|Annals of Oncology|2015|467
Systematic Review and Meta-Regression of Factors Affecting Midline Incisional Hernia Rates: Analysis of 14 618 Patients
|PLoS ONE|2015|385
Wound bed preparation: <scp>TIME</scp> for an update
|International Wound Journal|2016|206
Systematic Review and Meta-analysis of the Effect of Internal Iliac Artery Exclusion for Patients Undergoing EVAR
|European Journal of Vascular and Endovascular Surgery|2017|162
Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC)
|Annals of Oncology|2013|120